Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
This trial is designed for adults diagnosed with metastatic pancreatic ductal adenocarcinoma PDAC who have not yet received systemic treatment for their advanced cancer and have a good performance status. The study evaluates pumitamig, an investigational drug, in combination with chemotherapy to assess its safety and effectiveness. This phase II trial plans to explore different chemotherapy regimens combined with pumitamig to understand their impact on the disease.
Actively Recruiting
Researchers are evaluating IBI343 in people with locally advanced unresectable or metastatic solid tumors in a Phase IaIb, multicenter, open-label, first-in-human study. The trial aims to assess the safety, tolerability, how the drug moves through the body, and its effectiveness. The study includes participants from China, Australia, and the US and involves various stages to find the best dose and combination therapies. IBI343 is given intravenously and the study is divided into multiple parts. Phase Ia includes dose escalation, dose expansion, and dose optimization for monotherapy, with doses adjusted to balance benefits and risks. Phase Ib includes combination therapy with chemotherapy drugs like FOLFIRINOX or mFOLFOX, given every two to three weeks, with randomized groups to determine the optimal dose and safety. Participants will have regular visits for treatment and monitoring, including physical exams, laboratory tests, and imaging to measure tumor response using RECIST criteria. Safety is closely followed through adverse event tracking up to two years, along with assessments of drug levels in the body and immune response. The study also evaluates how tumor markers relate to treatment response, with total participation lasting up to two years.
Actively Recruiting
Researchers are evaluating an experimental drug called REGN7945 combined with another experimental drug, linvoseltamab, in adults with relapsed or refractory multiple myeloma. This is the first time REGN7945 is tested in humans, while linvoseltamab has been studied alone in similar patients. The study aims to assess the safety, tolerability, and effectiveness of REGN7945 with linvoseltamab compared to linvoseltamab alone. It also investigates side effects, the level of drug in the blood, immune response to the drugs, and impacts on pain, symptoms, function, and quality of life. Participants receive either REGN7945 plus linvoseltamab or linvoseltamab alone, administered according to the study protocol. The study includes Phase 1 and Phase 2 periods to evaluate initial safety and anti-tumor activity. Treatment and follow-up may continue for up to 5 years, allowing detailed monitoring of drug effects and participant outcomes. The trial uses a parallel design to compare the two treatment groups without random assignment. During the study, participants undergo regular assessments including blood tests to measure drug levels and immune responses, evaluations of disease status using international criteria, and questionnaires to assess quality of life and symptom changes. Researchers monitor side effects and overall response to treatment over time. The primary outcomes focus on treatment safety and tumor response within the first 12 weeks, while secondary outcomes include long-term safety, drug concentrations, immune reactions, symptom changes, and survival outcomes. Participation may last several years to fully capture these effects.
Actively Recruiting
Researchers are evaluating the safety, how the body processes and reacts to, and the early effects of ATG-037 alone and combined with Pembrolizumab in adults with locally advanced or metastatic solid tumors. This Phase I study aims to find the best dose and understand treatment impacts on patients whose cancer has progressed despite prior immune checkpoint inhibitor therapy. The trial is open-label, meaning both researchers and participants know the treatments being given, and it includes multiple centers to gather diverse data. The study has two main parts Part I involves dose escalation of ATG-037 given orally once daily initially, then twice daily in cycles of 21 days, followed by combination therapy with Pembrolizumab administered every three weeks for up to about two years. Part II explores ATG-037 given twice daily from the start in combination with Pembrolizumab. Pembrolizumab is given as a fixed 200 mg dose every three weeks. The study includes dose escalation and expansion phases to evaluate different dosing and combinations. Participants will undergo regular monitoring including safety evaluations for adverse events up to one year after the last dose. Researchers will measure drug levels in plasma, immune activity markers, and tumor responses using standard criteria. The study assesses outcomes like dose-limiting toxicities, maximum tolerated dose, and response rates to understand treatment effects. Participants are expected to provide informed consent, meet specific health criteria, and participate in scheduled visits and assessments throughout the treatment and follow-up periods.
Actively Recruiting
Researchers are studying an experimental drug called odronextamab combined with chemotherapy in patients with Diffuse Large B-cell Lymphoma DLBCL. This includes adults with untreated DLBCL as well as those whose disease has returned or not responded to treatment. The study aims to evaluate the safety, dosing, and effectiveness of odronextamab plus chemotherapy compared to the current standard treatment, rituximab combined with chemotherapy. The study is divided into Part 1A and 1B, which focus on determining safe doses and schedules of odronextamab combined with chemotherapy drugs including cyclophosphamide, doxorubicin, vincristine, and prednisone or prednisolone. Part 2 is a randomized comparison where participants receive either odronextamab plus chemotherapy or rituximab plus chemotherapy. Odronextamab and rituximab are given by intravenous infusion, with rituximab also possibly given subcutaneously. Participants will be monitored for side effects, disease progression, and quality of life over time. Assessments include measuring drug levels in the blood, immune response to the drug, and physical functioning questionnaires. The study will follow participants for up to five years to evaluate progression-free survival and other outcomes. Safety and adverse events will be tracked for up to two years.
Actively Recruiting
Researchers are studying linvoseltamab, either alone or combined with carfilzomib, compared to standard treatments for adults with relapsed or refractory multiple myeloma who have had one to three prior therapies. The purpose is to evaluate whether these treatments can provide deeper and longer-lasting responses and improve outcomes, while also examining safety and side effects. Participants will receive either linvoseltamab alone, linvoseltamab with carfilzomib, or one of several standard treatment combinations. The study is designed as an open-label, randomized trial where treatments are given according to protocol. The study may last up to several years to collect comprehensive data on treatment effects and side effects. During the trial, participants will undergo regular assessments including monitoring for adverse events, blood tests to measure drug levels and immune response, and evaluations of disease progression and quality of life. Researchers will measure outcomes such as treatment safety, disease response, survival, and patient-reported well-being over a follow-up period that can last up to five years after starting treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of different doses of IMG-007 compared to placebo in adults with moderate-to-severe active atopic dermatitis. This Phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to understand how well IMG-007 works and its safety profile over a period of up to 48 weeks. Participants will receive subcutaneous injections of IMG-007 or placebo according to the study protocol. The study includes multiple dose regimens of IMG-007 and placebo groups, with some placebo participants crossing over to receive IMG-007 later. Treatments follow a parallel group design where different groups receive different doses or placebo. During the study, participants will undergo assessments including Eczema Area and Severity Index EASI scoring and Investigator Global Assessment for Atopic Dermatitis vIGA-AD at baseline and Week 24. Researchers will monitor treatment-emergent adverse events throughout the study. Participants will be followed for up to 48 weeks to evaluate changes in skin condition and safety outcomes during and after treatment.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tacabrutideg compared with pirtobrutinib in adults with relapsed or refractory chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL who have previously been treated with a covalent Bruton tyrosine kinase inhibitor cBTKi. This phase 3, open-label, randomized study focuses on patients whose disease has relapsed or not responded after at least one line of therapy including a cBTKi. Participants will be randomly assigned to receive either tacabrutideg or pirtobrutinib, both given orally. The study compares the two drugs in parallel groups to assess their safety and efficacy over the course of treatment. During the study, participants will be closely monitored for disease progression, survival, response rates, duration of response, time to next treatment, adverse events, and quality of life using standardized questionnaires. These assessments will be conducted for up to approximately 3 years to evaluate the long-term outcomes and safety profiles of the treatments.
Actively Recruiting
Researchers are evaluating whether a combination of elranatamab, daratumumab, and lenalidomide provides better clinical benefits compared to a combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in people newly diagnosed with multiple myeloma who cannot have a transplant. This phase 3 study includes two parts the first focuses on safety, tolerability, and dose finding for elranatamab combinations, while the second compares treatment effectiveness and progression outcomes between the two combination therapies. Participants receive different drug combinations depending on the study part and assigned group. Part 1 evaluates elranatamab combined with daratumumab and lenalidomide or elranatamab with lenalidomide alone, focusing on dose levels. Part 2 randomly assigns participants to receive either elranatamab with daratumumab and lenalidomide or the comparator regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone. During the study, participants undergo regular assessments to monitor safety, treatment response, and disease progression, including measuring minimal residual disease negative complete response and progression-free survival. Researchers also track overall survival, adverse events, lab results, drug pharmacokinetics, and quality of life over an extended follow-up lasting up to approximately eight years after randomization.
Actively Recruiting
Researchers are evaluating the study medicine elranatamab, alone and combined with daratumumab, in people with multiple myeloma who have previously been treated with therapies including lenalidomide. The trial aims to determine whether elranatamab offers more benefit compared to a combination therapy of daratumumab, pomalidomide, and dexamethasone, while also assessing the safety and activity of elranatamab with daratumumab. This is a Phase 3, randomized, open-label study designed to compare these treatment options and to evaluate infection protection measures. The study includes three parts. Part 1 tests the safety and activity of different doses of elranatamab combined with daratumumab. In Part 2, participants are randomly assigned to receive elranatamab alone, elranatamab plus daratumumab, or the combination of daratumumab, pomalidomide, and dexamethasone. Part 3 assesses the impact of enhanced infection protection in participants receiving elranatamab alone or with daratumumab. Treatments are administered subcutaneously or orally as appropriate, and participants continue treatment until disease progression, unacceptable side effects, or withdrawal. Participants will undergo regular assessments including monitoring of disease progression, safety evaluations, and adverse event tracking. Key outcome measures include dose-limiting toxicities, progression-free survival, and treatment-emergent adverse events. Other evaluations include overall survival, response rates, duration of response, pharmacokinetics, immunogenicity, and quality of life assessments. Follow-up and monitoring continue for up to 51 months after randomization to capture long-term effects and safety.
1-10 of 17
1